具有抗瘤活性的口服非核酸STING激动剂
Bo-Sheng Pan1, Samanthi A Perera2, Jennifer A Piesvaux1
1Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, NJ, USA.
概括
研究人员发现MSA-2是一种口服的STING激动剂, 这种药物在小鼠模型中表现出瘤回归,持久免疫力和与抗PD-1疗法的协同作用,为癌症提供了有前途的治疗方法.
科学领域:
- 免疫学
- 药理学
- 癌症学
背景情况:
- 干扰素基因刺激 (STING) 途径是癌症免疫治疗的关键目标.
- 开发可口服的STING激动剂对于有效的癌症治疗至关重要.
研究的目的:
- 鉴定和描述一种新的口服可用的非核酸人类STING激动剂.
- 在临床前癌症模型中评估MSA-2的治疗潜力.
主要方法:
- 识别和合成MSA-2.
- 使用同源性小鼠瘤模型的体内研究.
- 对STING激活机制的分析 (单体-二元平衡).
- 评估与抗PD-1疗法的协同作用.
主要成果:
- MSA-2 耐受性很好,并刺激瘤中的干扰素β分泌.
- 口服和皮下使用MSA-2诱导瘤回归和持久的抗瘤免疫力.
- 在与抗PD-1治疗相结合时,MSA-2显示出协同作用.
- 由MSA-2激活需要二聚体形成,通过模仿瘤微环境的细胞外酸性增强.
结论:
- MSA-2是一种强效,可口服的STING激动剂,具有良好的安全性.
- 它的独特作用机制依赖于二聚体的形成,并由瘤微环境条件增强,支持其治疗效果.
- MSA-2 是全身癌症免疫治疗的有希望的候选药物,特别是在组合疗法中.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
420
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
420
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
490
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
490
Drugs that Stabilize Microtubules
2.5K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Drugs that Destabilize Microtubules
3.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.3K
Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
568
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
568


